{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:05:16Z","timestamp":1768881916383,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Optic neuritis, inflammation of the optic nerve, can cause visual impairment through retinal nerve fiber layer (RNFL) degeneration. Optical coherence tomography could serve as a sensitive noninvasive tool for measuring RNFL thickness and evaluating the neuroprotective effects of treatment. We conducted a meta-analysis to compare RNFL loss between novel add-on treatments and corticosteroid therapy at least 3 months after acute optic neuritis. The outcome measures were mean differences (MDs) in (1) RNFL thickness compared with the baseline in the affected and unaffected eye and (2) LogMAR visual acuity (VA). Seven studies involving five novel agents (memantine, erythropoietin, interferon-beta, phenytoin, and clemastine) were analyzed. When compared with the baseline RNFL thickness of the affected eye, the neuroprotective effects of novel add-on treatments could not be demonstrated. The difference in visual outcomes was also not significant between the two treatment groups. One study revealed that phenytoin has the potential to alleviate RNFL loss when the baseline thickness of the unaffected eye is considered. Larger randomized controlled trials with suitable outcome measures are warranted to evaluate the neuroprotective effects of novel treatments. Further studies should also tailor therapies to specific patient populations and investigate a more targeted treatment for acute optic neuritis.<\/jats:p>","DOI":"10.3390\/biomedicines10010192","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T20:46:03Z","timestamp":1642452363000},"page":"192","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neuroprotective Effects of Novel Treatments on Acute Optic Neuritis\u2014A Meta-Analysis"],"prefix":"10.3390","volume":"10","author":[{"given":"Tsung-Hsien","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Medical Education, National Taiwan University Hospital, Taipei 100, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5766-3057","authenticated-orcid":false,"given":"Chao-Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, Taipei 100, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Wei","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Taipei Tzu Chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3216-9540","authenticated-orcid":false,"given":"Teck-Boon","family":"Tew","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital Hsin-Chu Branch, HsinChu County 302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Ching","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, Taipei 100, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.survophthal.2019.06.001","article-title":"Critical review: Typical and atypical optic neuritis","volume":"64","author":"Abel","year":"2019","journal-title":"Surv. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1600-0420.1997.tb00147.x","article-title":"Residual symptoms and signs after untreated acute optic neuritis. A one-year follow-up","volume":"75","author":"Frederiksen","year":"1997","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(02)11919-2","article-title":"Management of acute optic neuritis","volume":"360","author":"Hickman","year":"2002","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/eye.2016.253","article-title":"Retinal ganglion cell and axonal loss in optic neuritis: Risk factors and visual functions","volume":"31","author":"Lee","year":"2017","journal-title":"Eye"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20851","article-title":"Quantifying axonal loss after optic neuritis with optical coherence tomography","volume":"59","author":"Costello","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","article-title":"Optical coherence tomography in multiple sclerosis: A systematic review and meta-analysis","volume":"9","author":"Petzold","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1474-4422(06)70573-7","article-title":"Optical coherence tomography in multiple sclerosis","volume":"5","author":"Frohman","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/brain\/awr264","article-title":"Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis","volume":"135","author":"Syc","year":"2012","journal-title":"Brain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00415-017-8531-y","article-title":"Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: A systematic review and meta-analysis","volume":"264","author":"Britze","year":"2017","journal-title":"J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","article-title":"A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis","volume":"72","author":"Hein","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s10072-020-04360-2","article-title":"Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis","volume":"41","author":"Yadegari","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: A randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"612097","DOI":"10.3389\/fneur.2020.612097","article-title":"Remedial Effect of Intravenous Cyclophosphamide in Corticosteroid-Refractory Patients in the Acute Phase of Neuromyelitis Optica Spectrum Disorder-Related Optic Neuritis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/1735-1995.158266","article-title":"Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial","volume":"20","author":"Salari","year":"2015","journal-title":"J. Res. Med. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00417-011-1894-3","article-title":"Memantine for axonal loss of optic neuritis","volume":"250","author":"Esfahani","year":"2012","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"S\u00fchs, K.W., Hein, K., Pehlke, J.R., K\u00e4smann-Kellner, B., and Diem, R. (2012). Retinal nerve fibre layer thinning in patients with clinically isolated optic neuritis and early treatment with interferon-beta. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051645"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00417-014-2925-7","article-title":"A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin","volume":"253","author":"Shayegannejad","year":"2015","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105741","DOI":"10.1016\/j.clineuro.2020.105741","article-title":"Randomized control trial of evaluation of Clemastine effects on visual evoked potential, nerve fiber layer and ganglion cell layer complex in patients with optic neuritis","volume":"193","author":"Moghaddasi","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jns.2015.02.019","article-title":"ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis","volume":"351","author":"Sergott","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1352458517742979","article-title":"Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial","volume":"25","author":"McKee","year":"2019","journal-title":"Mult. Scler. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.45.2.244","article-title":"Optic neuritis: A population-based study in Olmsted County, Minnesota","volume":"45","author":"Rodriguez","year":"1995","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2019-321653","article-title":"Case for a new corticosteroid treatment trial in optic neuritis: Review of updated evidence","volume":"91","author":"Petzold","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","article-title":"Retinal layer segmentation in multiple sclerosis: A systematic review and meta-analysis","volume":"16","author":"Petzold","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/brain\/awh365","article-title":"Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis","volume":"128","author":"Diem","year":"2005","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1152\/jn.00434.2003","article-title":"Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo","volume":"90","author":"Lo","year":"2003","journal-title":"J. Neurophysiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.0b013e3181aaea32","article-title":"Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis","volume":"73","author":"Naismith","year":"2009","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1523\/JNEUROSCI.23-18-06993.2003","article-title":"Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway","volume":"23","author":"Diem","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/brain\/awq146","article-title":"A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials","volume":"133","author":"Henderson","year":"2010","journal-title":"Brain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4103\/0301-4738.121071","article-title":"Evaluation of changes in retinal nerve fiber layer thickness and visual functions in cases of optic neuritis and multiple sclerosis","volume":"61","author":"Saxena","year":"2013","journal-title":"Indian J. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.ophtha.2011.11.032","article-title":"Ganglion cell loss in relation to visual disability in multiple sclerosis","volume":"119","author":"Walter","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1352458517708463","article-title":"Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis","volume":"24","author":"Balk","year":"2018","journal-title":"Mult. Scler. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"540156","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front. Neurol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/192\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:02:50Z","timestamp":1760133770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["biomedicines10010192"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10010192","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}